Funded project
Equity
Turn Biotechnologies

Turn Biotechnologies

Ageing
Age-related diseases
Cellular reprogramming
Turn Bio develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. They are reprogramming the epigenome – a network of chemical compounds and proteins controlling cell functions to restore capabilities that are lost with age.
Funding
$ 1,000,000
Initiated
3.12.2021
Approval
100% Voted Yes
Anja Kramer
CEO
Marco Quarta
Co-founder
Vittorio Sebastiano
Co-founder
AT A GLANCE

Stage: Developing pre-clinical efficacy data. Series A anticipated Q1/Q2 2022

Area: Cellular reprogramming

Status: Ongoing

Patent: Already patented technology

PROJECT LINKS

Background

Turn Biotechnologies, Inc. (“Turn.Bio”, mailing address: 548 Market St. Pmb 23131, San Francisco, Ca 94104) is a pre-clinical start-up based on Stanford University Intellectual Property (IP) developed from 2016 onwards based on the work of Vittorio Sebastiano, Ph.D. and Jay Shakar, Ph.D. (Institute of Stem Cell Biology and Regenerative Medicine, Stanford Univ.) (ERA™) and Marco Quarta, Ph.D. (Center for Tissue Regeneration, Repair, and Restoration, Stanford School of Medicine) (AN™) .

Turn.Bio’s focus is a translational program based on the Sebastiano, Shakar, and Quarta research into mRNA and epigenomic reprogramming to restore aging-related loss of function. The developments have evolved into both an mRNA payload development system (ERA™ / AN ™) and a delivery system based on lipid nanoparticles. Both payload and delivery IP are licensed exclusively by Turn.Bio through a combined royalty license agreement with Stanford.

Aims, Hypothesis & Results

Turn.Bio is moving to the next stage in their corporate development – preclinical efficacy testing. The experiments for the ultimate dermatology and ophthalmology indications will lead their pre-clinical efficacy data generation efforts in Q4 '2021, with data available in Q1’2022.

The new round of funding Turn is raising, a relatively small (up to $10M USD) convertible note (non-priced, with a valuation cap) is positioned as ensuring the ability to fully execute, with contingencies, further developing pre-clinical efficacy data important to the Series A negotiations anticipated in Q1/Q2’2022.

Timeline

Pre-Clinical efficacy testing: dermatology and ophthalmology

  • Data generation Q4 2021
  • Data available Q1 2022

Investment: $1.0 mil
Status: Ongoing
Duration: Until ROI

VitaDAO Board Evaluation Writeup

Turn.Bio has sufficient funds to continue operating at the current burn rate until the end of the year, assuming no other funds. However, existing investors have indicated their intent to participate in this funding round.

In that case, should no other external parties, including the Fund, participate in the convertible note round, Turn.Bio could continue to operate and complete their efficacy studies on schedule. At that point, the company would need to either proceed to a Series A, and defer Phase 2 GLP material orders until the Series A was closed (with a 6-month window available for this process if necessary) or seek other funding arrangements.

Additionally, there is no reason to suggest that Turn.Bio will not also complete their co-development agreements with Pharma partners, which will add more capital to available funds. At which point, current partners and new Pharma partners could effectively fund Turn.Bio through to Series A even if they face some delays during the efficacy trials or protracted Series A negotiations.

In summary, management has the necessary flexibility to achieve targets relying only on existing partners if needed, though at the expense of time and potential lost opportunity on valuation due to any loss of interest in biotech/pharma by VCs.

Projects supported

Non Consectetur Necessitatibus

Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa

$293,00
raised
View Project

Dolorum Quia

Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex

$293,00
raised
View Project

Eum Harum Asperiores Id

Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin

$293,00
raised
View Project

Ex Temporibus Perferendis

Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda

$293,00
raised
View Project

Culpa Possimus

Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod

$293,00
raised
View Project

Earum Est Dolorem

Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus

$293,00
raised
View Project

Aperiam Et Quis Et

Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s

$293,00
raised
View Project

Voluptas Quam Sapiente

Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u

$293,00
raised
View Project

Aut Accusantium Ut

Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita

$293,00
raised
View Project

Nisi

Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l

$293,00
raised
View Project
Latest Project Updates
No items found.
3
December
2021
Project Initiated!

Discover more projects & initiatives

ApoptoSENS - Senolytic CAR-NK Cells

IP-NFT

Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.

$ 253,000
raised
View Project

Scheibye-Knudsen Lab

IP-NFT

What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.

$ 250,000
raised
View Project

Discovery of novel mitophagy activators for Alzheimer’s disease

IP-NFT

Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.

$ 300,000
raised
View Project

Rubedo.Life

Equity

Rubedo is building a platform for longevity medicines using “smart drugs” (prodrugs) that have the capacity to selectively be activated in target cells predicted to be pathogenic and the cause of age-related diseases.

$ 350,000
raised
View Project

Are you working on the next longevity science breakthrough?

Apply for funding

About VitaDAO

Who can apply?
What types of projects do you fund?
What is the application structure?
Who owns IP from funded projects?
What project stages do you fund?